Alto Neuroscience (ANRO)

• Market cap: $1.11B
• 1 day: 0.7%
• 5 days: 6.19%
• 1 month: 11.56%
• 3 months: 19.11%
• 6 months: 70.25%
• Year to date: 72.81%
• 1 year: 836.93%
• 5 years: 38.5%
• 10 years: 38.5%
• Sector: Healthcare
• Industry: Biotechnology

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 68